Lamivudine for hepatitis B after liver transplantation

Liver Transplantation

Volumn 7, Issue 6, 2001, Pages 511-512

  Mutimer, David ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIVIRUS AGENT; BILIRUBIN; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EDITORIAL; FOLLOW UP; GRAFT FAILURE; GRAFT INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNOPROPHYLAXIS; LIVER TRANSPLANTATION; LONG TERM CARE; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; REINFECTION; SEROCONVERSION; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0034969207     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.24934     Document Type: Article

References (14)

1. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
2. Long term incidence of hepatitis B resistance to lamivudine in human immunodeficiency virus-infected patients
3. Selection of hepatitis B surface "escape" mutants during passive immune prophylaxis following liver transplantation: Potential impact of genetic changes on polymerase protein function
4. Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation
5. Lamivudine treatment for acute hepatitis B after liver transplantation
6. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
7. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up
8. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation
9. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
10. Lamivudine for hepatitis B in liver transplantation: A single-center experience
11. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
12. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
13. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
14. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants